2.2. Study Endpoints
The primary endpoint was the percent change in LDL-C for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism. Secondary endpoints included the percent change in hsCRP, high-density lipoprotein cholesterol (HDL-C), total cholesterol, and serum triglycerides between subgroups.